HIV RNA suppression among HIV-infected Ugandan children with Measles

Journal of Acquired Immune Deficiency Syndromes

Volumn 48, Issue 2, 2008, Pages 225-227

  Ruel, Theodore D ^a   Achan, Jane ^b   Gasasira, Anne F ^b   Charlebois, Edwin D ^a   Mehbratu, Tsedal ^a   Rosenthal, Philip J ^a   Dorsey, Grant ^a   Kamya, Moses R ^a   Kekitiinwa, Adeodata ^c   Wong, Joseph ^a   Havlir, Diane V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAKERERE UNIVERSITY   (Uganda)

^c MULAGO HOSPITAL   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES VACCINE; VIRUS RNA;

CD4 LYMPHOCYTE COUNT; CELL DEATH; EPIDEMIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LETTER; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTOPENIA; MEASLES; PRIORITY JOURNAL; UGANDA; VIRUS INHIBITION; WORLD HEALTH ORGANIZATION; BLOOD; CHILD; HUMAN IMMUNODEFICIENCY VIRUS; INFANT; PHYSIOLOGY; PRESCHOOL CHILD; VIROLOGY; VIRUS REPLICATION;

CHILD; CHILD, PRESCHOOL; HIV; HIV INFECTIONS; HUMANS; INFANT; MEASLES; RNA, VIRAL; VIRUS REPLICATION;

EID: 46449111256     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e31816d9c86     Document Type: Letter

References (12)

1. Mole L, Ripich S, Margolis D, et al. The impact of active herpes simplex virus infection on human immunodeficiency virus load. J Infect Dis. 1997;176:766-770.
2. Watt G, Kantipong P, de Souza M, et al. HIV-1 suppression during acute scrub-typhus infection. Lancet. 2000;356:475-479.
3. Moss WJRJ, Monze M, Cutts F, et al. Suppression of human immunodeficiency virus replication during acute measles. J Infect Dis. 2002;185:1035-1042.
4. Lievano FA, Papania MJ, Helfand RF, et al. Lack of evidence of measles virus shedding in people with inapparent measles virus infections. J Infect Dis. 2004;189(Suppl 1):S165-S170.
5. Kamya MR, Gasasira AF, Achan J, et al. Effects of trimethoprim- sulfamethoxazole and insecticide-treated bednets on malaria among HIV-infected Ugandan children. AIDS. 2007; 21:2059-2066.
6. Vaccine Assessment and Monitoring Team of the Department of Vaccines and Biologicals, WHO. WHO-recommended standards for surveillance of selected vaccine-preventable diseases. 2003. Available at http://www.who. int/vaccines-documents/DocsPDF06/843.pdf. Accessed March 7, 2008.
7. Riddell MA, Byrnes GB, Leydon JA, et al. Dried venous blood samples for the detection and quantification of measles IgG using a commercial enzyme immunoassay. Bull World Health Organ. 2003;81:701-707.
8. Riddell MA, Leydon JA, Catton MG, et al. Detection of measles virus-specific immunoglobulin M in dried venous blood samples by using a commercial enzyme im-munoassay. J Clin Microbiol. 2002;40:5-9.
9. Ryon JJ, Moss WJ, Monze M, et al. Functional and phenotypic changes in circulating lymphocytes from hospitalized Zambian children with measles. Clin Diagn Lab Immunol. 2002; 9:994-1003.
10. Garcia M, Yu X-F, Griffin DE, et al. In vitro suppression of human immunodeficiency virus type 1 replication by measles virus. J Virol. 2005;79:9197-9205.
11. Grivel J-C, Garcia M, Moss WJ, et al. Inhibition of HIV-1 replication in human lym-phoid tissues ex vivo by measles virus. J Infect Dis. 2005;192:71-78.
12. Okada H, Sato TA, Katayama A, et al. Comparative analysis of host responses related to immunosuppression between measles patients and vaccine recipients with live attenuated measles vaccines. Arch Virol. 2001;146: 859-874.